This agreement significantly de-risks Manulife's balance sheet by transferring substantial long-term care (LTC) biometric risk to Munich Re. It frees up capital for Manulife and provides Munich Re with a large block of business, potentially improving both companies' financial stability and capital efficiency. The deal highlights the ongoing trend of insurers offloading legacy LTC liabilities.
This reinsurance agreement is a significant positive for Manulife, as it offloads a substantial portion of its long-term care biometric risk, which has historically been a volatile and capital-intensive segment for insurers. This frees up capital that Manulife can deploy more efficiently, potentially leading to increased shareholder returns or investments in higher-growth areas. For Munich Re, it represents a large acquisition of reinsurance business, bolstering its presence in the US life and health reinsurance market. The deal underscores the broader trend in the insurance sector of companies seeking to manage and reduce their exposure to legacy long-term care liabilities. This could encourage other insurers with similar exposures to explore similar de-risking strategies, potentially creating opportunities for reinsurers.